Gerresheimer has announced that it will manufacture supplies of Iconovo’s IcoOne dry powder inhaler for Phase 3 trials of ISR’s intranasal COVID-19 vaccine and has started the design process for molding and manufacturing the device. In March 2021, Iconovo announced that it would develop an inhaled vaccine for ISR, and in July 2021, Icovono said that it was developing an intranasal version of the ICOone device for the ISR vaccine. According to the announcement, ISR is currently preparing to initiate a Phase 1/2 study of the vaccine in Dhaka, Bangladesh.
ISR CEO Ola Winqvist commented, “We have signed a very important agreement to be able to produce large enough quantities of our game changing inhaler, to cover the needs of our late-stage development studies and our pivotal Phase 3 program. This agreement also opens the door for further collaborations with Gerresheimer, to produce sufficient quantities of our inhaler to secure our commercial supply chain and the global launch of our exciting dry powder SARS-CoV-2 vaccine.”
Gerresheimer Medical Systems Executive VP Sales & Marketing, Administration & TCC, Manfred Baumann said, “We are happy and delighted to support ISR with our high expertise in the development, industrialization and manufacturing of drug delivery devices. With our annual production of more than 100 million inhalers we are the ideal partner for ISR.”
Read the Gerresheimer press release.
